BridgeBio Pharma, Inc. (BBIO) vs Halozyme Therapeutics, Inc. (HALO)
A side-by-side comparison of BridgeBio Pharma, Inc. and Halozyme Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBIO
BridgeBio Pharma, Inc.
$67.46HealthcareDelayed quote: Oct 6, 2026, 9:45 AM EDT
HALO
Halozyme Therapeutics, Inc.
$109.70HealthcareDelayed quote: Oct 6, 2026, 9:40 AM EDT
Total return — BBIO vs HALO
growth of $100 · dividends reinvested · last 7yBBIO +140.1% (+13.3%/yr)HALO +563.7% (+31.0%/yr)HALO compounded faster over this window
BBIO HALO
BBIO vs HALO: by the numbers
- •BBIO is the larger company ($13.21B vs $13.01B market cap).
- •HALO is profitable (24.86% net margin) while BBIO runs a net loss (-97.64%).
- •BBIO grew revenue faster over the past five years (62.61% vs 32.18% CAGR).
Metrics side by side
Valuation
| Metric | BBIO | HALO |
|---|---|---|
| P/E ratio | N/A | 32.75 |
| Forward P/E | N/A | 13.04 |
| PEG ratio | N/A | 1.43 |
| P/S ratio | 18.53 | 7.82 |
| P/B ratio | N/A | 90.65 |
| EV / EBITDA | N/A | 14.22 |
| FCF yield | N/A | 6.20% |
Profitability
| Metric | BBIO | HALO |
|---|---|---|
| Gross margin | 93.35% | 78.18% |
| Operating margin | -113.35% | 56.77% |
| Net margin | -97.64% | 24.86% |
| ROE | N/A | 288.13% |
| ROIC | -62.14% | 27.42% |
Growth (annualized)
| Metric | BBIO | HALO |
|---|---|---|
| Revenue CAGR (5Y) | 62.61% | 32.18% |
| EPS CAGR (5Y) | N/A | 22.68% |
| FCF CAGR (5Y) | N/A | 40.08% |
| Total return CAGR (5Y) | 7.38% | 22.18% |
Frequently asked
- Which has grown faster, BBIO or HALO?
- Over the past five years, BBIO grew revenue faster — BBIO at a 62.61% CAGR versus HALO at 32.18%.
- Is BBIO or HALO more profitable?
- HALO runs the higher net margin — BBIO at -97.64% versus HALO at 24.86%.
- How have BBIO and HALO total returns compared?
- Over the past 5 years, BBIO delivered 7.38% and HALO delivered 22.18% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Halozyme Therapeutics P/E ratioBridgeBio Pharma ROEHalozyme Therapeutics ROEBridgeBio Pharma operating marginHalozyme Therapeutics operating marginBridgeBio Pharma revenue growthHalozyme Therapeutics revenue growthBridgeBio Pharma free cash flowHalozyme Therapeutics free cash flow
BridgeBio Pharma & Halozyme Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.